Results 21 to 30 of about 29,486 (214)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Abela, Irene A, Amico, Patrizia, Audigé, Annette, Braun, Dominique L, Briel, Matthias, Bucher, Heiner C, Chammartin, Frédérique, Eichenberger, Anna L, Günthard, Huldrych F, Hasse, Barbara, Koller, Michael T, Kusejko, Katharina, Mueller, Nicolas J, Müller, Thomas F, Rauch, Andri, Schuurmans, Macé M, Speich, Benjamin, Stoeckle, Marcel P, Tamm, Michael, Trkola, Alexandra   +19 more
core   +6 more sources

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP [PDF]

, 2023
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Design Matched cohort study, emulating a comparative effectiveness trial.
Andrews, Colm D, Bacon, Sebastian CJ, Curtis, Helen J, Goldacre, Ben, Hernán, Miguel A, Horne, Elsie MF, Hulme, William J, Keogh, Ruth H, MacKenna, Brian, Mehrkar-Asl, Amir, Morley, Jessica, Palmer, Tom M, Parker, Edward PK, Sterne, Jonathan AC, Walker, Alex J, Walker, Venexia, Williamson, Elizabeth J   +16 more
core   +5 more sources

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study

Journal of the Formosan Medical Association, 2023
Background/Purpose: MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.
Szu-Ting Huang, Yu-Shan Huang, Wang-Da Liu, Sung-Ching Pan, Hsin-Yun Sun, Chia-En Lien, Charles Chen, Szu-Min Hsieh   +7 more
doaj   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

Clinical Case Reports, 2022
In this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms.
Suresh Babu Chellapandian, Suha Turkmen, Imtiaz Salim, Shanmugavel Chinnakaruppan, Jassim Mohammad   +4 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial

EClinicalMedicine, 2022
Summary: Background: Although effective mRNA vaccines for SARS-CoV-2 infection have been deployed worldwide, their interchangeability could facilitate the scale-up of vaccination programs.
Cécile Janssen, Marine Cachanado, Laetitia Ninove, Marie Lachatre, Jocelyn Michon, Olivier Epaulard, Zoha Maakaroun-Vermesse, Christian Chidiac, Bruno Laviolle, Hugues Aumaitre, Ady Assaf, Karine Lacombe, Catherine Schmidt-Mutter, Elisabeth Botelho-Nevers, Magali Briere, Thomas Boisson, Paul Loubet, Boris Bienvenu, Olivier Bouchaud, Amel Touati, Christine Pereira, Alexandra Rousseau, Laurence Berard, Melissa Montil, Xavier de Lamballerie, Tabassome Simon, Odile Launay   +26 more
doaj   +1 more source

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Vaccines, 2023
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal   +10 more
doaj   +1 more source

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Frontiers in Immunology, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson   +17 more
doaj   +1 more source

Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants [PDF]

, 2022
Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving three ...
Belik, Milja, Häkkinen, Hanni K., Ivaska, Lauri, Jalkanen, Pinja, Julkunen, Ilkka, Kakkola, Laura, Kantele, Anu, Kolehmainen, Pekka, Laine, Larissa, Lempainen, Johanna, Lundberg, Rickard, Miettinen, Simo, Naves, Rauno A., Ortamo, Eeva, Pakkanen, Sari H., Pasternack, Arja, Reinholm, Arttu, Ritvos, Mikael A., Ritvos, Olli, Sironen, Tarja, Skön, Marika, Tahtinen, Paula A., Vapalahti, Olli, Väisänen, Elina, Österlund, Pamela   +24 more
core   +1 more source